Currently submitted to: JMIR Cancer
Date Submitted: Jan 27, 2026
Open Peer Review Period: Feb 3, 2026 - Mar 31, 2026
(closed for review but you can still tweet)
NOTE: This is an unreviewed Preprint
Warning: This is a unreviewed preprint (What is a preprint?). Readers are warned that the document has not been peer-reviewed by expert/patient reviewers or an academic editor, may contain misleading claims, and is likely to undergo changes before final publication, if accepted, or may have been rejected/withdrawn (a note "no longer under consideration" will appear above).
Peer review me: Readers with interest and expertise are encouraged to sign up as peer-reviewer, if the paper is within an open peer-review period (in this case, a "Peer Review Me" button to sign up as reviewer is displayed above). All preprints currently open for review are listed here. Outside of the formal open peer-review period we encourage you to tweet about the preprint.
Citation: Please cite this preprint only for review purposes or for grant applications and CVs (if you are the author).
Final version: If our system detects a final peer-reviewed "version of record" (VoR) published in any journal, a link to that VoR will appear below. Readers are then encourage to cite the VoR instead of this preprint.
Settings: If you are the author, you can login and change the preprint display settings, but the preprint URL/DOI is supposed to be stable and citable, so it should not be removed once posted.
Submit: To post your own preprint, simply submit to any JMIR journal, and choose the appropriate settings to expose your submitted version as preprint.
Warning: This is an author submission that is not peer-reviewed or edited. Preprints - unless they show as "accepted" - should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.
Cost-Effectiveness of AIDPATH-Generated CAR-T Therapy for Multiple Myeloma in Germany: A 40-Year Hospital-Perspective Analysis
ABSTRACT
Background:
Although effective, current CAR-T production methods — centralized, manual, and complex — are cost-intensive, time-consuming, and prone to variability. AIDPATH proposes a decentralized, automated alternative that integrates patient-specific data, optimizes resource use, and potentially improves cell viability, manufacturing efficiency, and patient outcomes.
Objective:
The aim of this study was to compare AIDPATH-produced CAR-T therapy to both Cilta-Cel and standard of care (SoC) for triple-class refractory multiple myeloma (MM) patients, over a 40-year time horizon in Germany from the hospital perspective.
Methods:
A partitioned survival model reflecting 3 health states (progression-free disease, progressed disease, and death) was used. The analysis used clinical trial data for Cilta-Cel, real-world data for SoC, and estimated parameters for AIDPATH, due to the developmental status of the platform. The primary outcome was the incremental cost effectiveness ratio, secondary outcomes included sensitivity and scenario analyses.
Results:
AIDPATH was dominant compared to both Cilta-Cel and SoC. Most costs for CAR-T therapies were driven by acquisition and adverse events. Sensitivity analyses showed the results were most influenced by discount rates and assumptions about progression-free survival. Scenario analyses, including reduced adverse events and shorter vein-to-vein time for AIDPATH, further supported its cost-effectiveness.
Conclusions:
This is the first study to assess the cost-effectiveness of CAR-T product generated with AI support in Germany from the hospital perspective. AIDPATH was found to be a cost-effective alternative to both Cilta-Cel and SoC, making it a promising option for future implementation. While further data are needed, this study provides valuable guidance for health care stakeholders, reimbursement discussions, and future research.
Citation
Request queued. Please wait while the file is being generated. It may take some time.
Copyright
© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.